MID-REGIONAL PROADRENOMEDULLIN (MR-PROADM) AS A BIOMARKER IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION - STUDY CONTINUATION

Abstract

Objective: Assessment of MR-proADM serum concentration as a biomarker in patients with CKD and arterial hypertension. Design and method: Our study included a single-center cohort of 160 patients admitted to the Second Department of Nephrology and Hypertension with Dialysis Unit Medical University of Bialystok with CKD treated conservatively. The concentration of MR-proADM were measured in the serum of patients and the control group (27 healthy volunteers). The statistical analysis included past medical history, the stages of CKD, the presence and degree of control of arterial hypertension, and the presence of cardiovascular diseases. Results: Patients with CKD had higher serum MR-proADM concentrations compared to the control group (62,61 [45,67–81,39] vs 224 [143,95–293,35] pg/mL, p < 0,0001). The median MR-proADM concentration in each stage was not statistically different. There was a significant positive correlation between MR-proADM and the dimension of the left ventricle (R = 0,25; p = 0,009) with glucose concentration (R = 0,19; p = 0,017) and a negative correlation with serum iron concentration (R = -0,20; p = 0,03). There were no significant differences in the plasma concentration of MR-proADM depending on the degree of hypertension control. Conclusions: In larger group of CKD patients, an increased serum concentration of MR-proADM was confirmed. Left ventricular hypertrophy found in echocardiography was associated with higher serum concentrations of MR-proADM. To assess the usefulness of this hormone as a prognostic biomarker of CKD or cardiovascular risk, further studies in larger groups still are required.